Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23638941 | 0.84 | SCN9A (0.52) | SCN9ADRD2DRD3 | |
| SCHEMBL21294747 | 0.83 | SCN9A (0.51) | SCN9AHTR2C | |
| SCHEMBL20063536 | 0.81 | SCN9A (0.46) | SCN9ADRD2HTR2C | |
| SCHEMBL23638950 | 0.81 | SCN9A (0.48) | SCN9ADRD2HTR2CCHRM2HTR1A | |
| SCHEMBL23639026 | 0.81 | SCN9A (0.47) | SCN9ADRD2HTR2CCHRM2HTR1A | |
| SCHEMBL23140869 | 0.80 | HTR2C (0.47) | SCN9ADRD2HTR2C | |
| SCHEMBL21306730 | 0.80 | HTR2C (0.47) | SCN9ADRD2HTR2CHTR2B | |
| SCHEMBL21306610 | 0.80 | SCN9A (0.49) | SCN9ADRD2 | |
| SCHEMBL20063933 | 0.80 | SCN9A (0.49) | SCN9ADRD2 | |
| SCHEMBL20073015 | 0.80 | SCN9A (0.49) | SCN9ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1478/4885DRD2 1844/4885HTR2C 1243/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | SCN9A 1478/4885DRD2 1844/4885HTR2C 1243/4885 |
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, CACNA1A, SCN1A | SCN9A 34/4885DRD2 1985/4885HTR2C 1563/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1501/4885DRD2 1936/4885HTR2C 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.